- Home
- NSIT vs RNA Comparison
NSIT vs RNA Comparison
Compare NSIT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSIT
- RNA
- Stock Information
- Founded
- NSIT 1988
- RNA 2012
- Country
- NSIT United States
- RNA United States
- Employees
- NSIT N/A
- RNA N/A
- Industry
- NSIT EDP Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- NSIT Technology
- RNA Health Care
- Exchange
- NSIT Nasdaq
- RNA Nasdaq
- Market Cap
- NSIT 2.8B
- RNA 4.0B
- IPO Year
- NSIT 1995
- RNA 2020
- Fundamental
- Price
- NSIT $88.69
- RNA $70.64
- Analyst Decision
- NSIT Buy
- RNA Buy
- Analyst Count
- NSIT 2
- RNA 20
- Target Price
- NSIT $142.50
- RNA $69.26
- AVG Volume (30 Days)
- NSIT 490.7K
- RNA 10.5M
- Earning Date
- NSIT 10-30-2025
- RNA 11-10-2025
- Dividend Yield
- NSIT N/A
- RNA N/A
- EPS Growth
- NSIT N/A
- RNA N/A
- EPS
- NSIT 4.21
- RNA N/A
- Revenue
- NSIT $8,271,548,000.00
- RNA $20,868,000.00
- Revenue This Year
- NSIT N/A
- RNA N/A
- Revenue Next Year
- NSIT $3.42
- RNA $108.97
- P/E Ratio
- NSIT $21.03
- RNA N/A
- Revenue Growth
- NSIT N/A
- RNA 106.27
- 52 Week Low
- NSIT $87.45
- RNA $21.51
- 52 Week High
- NSIT $181.92
- RNA $71.09
- Technical
- Relative Strength Index (RSI)
- NSIT 19.18
- RNA 79.61
- Support Level
- NSIT $89.57
- RNA $69.67
- Resistance Level
- NSIT $92.82
- RNA $71.09
- Average True Range (ATR)
- NSIT 3.23
- RNA 0.31
- MACD
- NSIT -0.24
- RNA -0.50
- Stochastic Oscillator
- NSIT 5.58
- RNA 74.21
About NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.